Novavax, Inc. (NVAX)
|Net Income (ttm)||-615.11M|
|Trading Day||May 13|
|Day's Range||117.12 - 133.44|
|52-Week Range||37.37 - 331.68|
If Novavax is successful, it could generate billions.
Human trials of the combination vaccine are expected to start later this year.
Novavax Vaccine in 'Good Shape' for Approval Filing: CEO
May.12 -- Novavax Inc. CEO Stan Erck says manufacturing challenges are behind the delay in the company's plan to file for authorization of its Covid-19. He speaks on "Bloomberg Markets: European Close.
Novavax, Inc. (NASDAQ:NVAX) shares are trading lower by 3.7% at $133.05 after JPMorgan downgraded the stock from Overweight to Neutral and lowered its price target from $285 to $161 per share. Novavax i...
The stock price of Novavax has seen a large 18% drop in just five trading sessions. The decline was driven partly due to the company's announcement that it doesn't plan to file for authorization for its...
The European Commission president has provided some hints that a supply agreement with Novavax could be on the way.
An analyst's price target cut reflected an uncomfortable new reality for the biotech.
Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.
The patent waiver matter will likely prove to be a "nonissue," while NVAX stock has many upcoming, positive catalysts. The post Ahead of Positive Catalysts, Novavax Stock Is Attractive on Weakness appea...
Novavax Inc (NASDAQ: NVAX) delayed ramping up COVID-19 vaccine production again on Monday and said it was unlikely to seek regulatory approval for its shot in Europe, UK, and the United States until Q3 ...
The Covid-19 treatment response process includes a number of different major players, including Pfizer Inc (NYSE: PFE), BioNTech SE – ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), AstraZeneca plc (NAS...
Vaccine stocks had a rough week, with Novavax stock down almost -25%, Moderna down by about -9%, and Pfizer stock up by just about 2% despite posting a very solid set of first-quarter results. The decli...
It had nothing to do with the company's financial performance.
Novavax, Inc (NASDAQ: NVAX) shares fell over 12% in the after-hours trading on Monday after closing almost 8.8% lower in regular trading. What Happened: The after-hours dip came as the Maryland-based co...
In the latest trading session, Novavax (NVAX) closed at $160.50, marking a -8.81% move from the previous day.
Novavax (NVAX) delivered earnings and revenue surprises of -15.09% and 53.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
The company's latest coronavirus vaccine news produced an unpleasant side effect.
Novavax Inc said on Monday it will ramp up production of its COVID-19 vaccine slower than it had previously anticipated and does not expect to file for regulatory approval in the United States, Britain ...
Shares of Novavax (NASDAQ:NVAX) rose after the company reported Q1 results. Quarterly Results Earnings per share were down 425.86% over the past year to ($3.05), which beat the estimate of ($3.60).
GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial r...
A big capital gains tax is looming, threatening to trigger a selloff on companies whose stock ran up the most. The post 7 Stocks Most at Risk of a Capital Gains Tax Selloff appeared first on InvestorPl...
Novavax, Inc. (NVAX) announced positive results from the animal study of its combo vaccine for influenza and COVID-19. The positive news however did little to stem the sell-off in shares that began in l...
Novavax (NASDAQ: NVAX) shares are trading lower amid reports competing COVID-19 vaccines may be approved in Europe. The stock also dipped on reports the company is unlikely to seek emergency use authori...
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
- Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus - Data shared via preprint server for biology, bioRxiv, ahead of public...
Final Trades: American Tower, Novavax, Small caps & more
The "Halftime Report" traders give their top picks to watch for the second half.
The danger is overstated.
Oppenheimer health care analyst on whether vaccine makers should lose sleep over patent waivers
Hartaj Singh, Oppenheimer & Co, on Covid vaccine makers under pressure as the patent waiver conversation continues. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Pete Najarian, Jeff Mil...
Pfizer fell Thursday by as much as 5% from Wednesday's close while Moderna dipped by almost 12% before both stocks recovered most of those losses.
U.S. backs COVID-19 vaccine patent waiver
Yahoo Finance's Brian Sozzi, Myles Udland, Julie Hyman, and Anjalee Khemlani discuss what the vaccine patent waiver means for Moderna's business.
Novavax to deliver 350 million doses beginning Q3 2021 1.1 billion doses of Novavax vaccine to be available to countries participating in COVAX Serum Institute of India to provide balance of doses for L...
If enacted, such a move would hit the smaller vaccine makers particularly hard.
Vaccine makers sink as Biden considers waving patents
Brent Saunders, former Allergan CEO, on who will make the vaccine next time. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Dan Nathan and Nadine Terman.
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 ...
GAITHERSBURG, Md., May 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication ...
It may offer key COVID program updates.
Showered with optimism in April, shareholders will have to wait for the bloom.
Berkshire Hathaway, Pfizer, Novavax and Amazon were our top stock trades for Tuesday. Now, let's get a look at the charts as we kickoff May.
Shares of coronavirus vaccine developer Novavax, Inc. (NASDAQ: NVAX) were moving sharply to the downside on above-average volume Monday. The move comes despite the company announcing that it has added a...
Find out what was responsible for the Nasdaq missing out on gains.
NVAX stock is losing today, even with two big announcements this morning. Speculators seem to think these announcements will lead to delays.
Novavax Inc (NASDAQ: NVAX) has told the European Union it plans to begin delivering its COVID-19 vaccine to the bloc towards the end of this year, A formal contract could be signed as early as this week...
Investors don't like the timing of a potential supply deal with the EU.
Novavax Inc (NASDAQ: NVAX) has initiated a pediatric expansion of its Phase 3 PREVENT-19 trial for NVX-CoV2373, its COVID-19 vaccine candidate. The additional arm of the ongoing PREVENT-19 pivotal trial...
GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has init...
In the latest trading session, Novavax (NVAX) closed at $236.93, marking a -0.25% move from the previous day.
According to an SEC filing, Novavax Inc (NASDAQ: NVAX) has received an additional $147.3M as part of Operation Warp Speed to develop a COVID-19 vaccine dubbed NVX-CoV2373. This addition brings its total...
Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate... [Read more...]
|IPO Date |
Dec 5, 1995
|Stock Exchange |
|Ticker Symbol |
In 2020, Novavax's revenue was $475.60 million, an increase of 2,448.48% compared to the previous year's $18.66 million. Losses were -$418.26 million, 215.2% more than in 2019.
According to 7 analysts, the average rating for Novavax stock is "Buy." The 12-month stock price forecast is 294.00, which is an increase of 142.23% from the latest price.